Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS:

• Histologically confirmed diagnosis of 1 of the following:
• Chronic lymphocytic leukemia (CLL)
• B-cell small lymphocytic leukemia (SLL)
• Any marginal zone lymphoma
• Grade 1-3A follicular lymphoma
• Waldenstrom's macroglobulinemia
• Mantle cell lymphoma
• No transformed indolent lymphoma
• Assessable disease (phase I)
• Measurable disease (phase I and II), defined as ≥ one lesion that can be accurately measured in ≥ 1 dimension as ≥ 2 cm by conventional techniques OR ≥ 1 cm by spiral CT scan
• Lymph nodes measuring ≤ 1 cm in the short axis are considered normal
• Relapsed or refractory disease
• Must have received at least 1 prior therapeutic regimen but no more than 3 prior conventional cytotoxic therapy regimens
• No known brain metastases or meningeal disease

PATIENT CHARACTERISTICS:

• Karnofsky performance status > 50%
• Absolute neutrophil count > 1, 000/mcl (more than 500/mcl if known lymphomatous involvement)
• Platelet count ≥ 50,000/mcl
• Total bilirubin 50 mL/min
• Patients may have febrile episodes up to 38.5ºC without evidence of active infection
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No New York Heart Association class III or IV congestive heart failure
• No uncontrolled intercurrent illness, including any of the following:
• Ongoing or active infection
• Cerebrovascular accident or transient ischemic attack within 6 months of study entry
• Unstable angina pectoris
• Cardiac arrhythmia
• EKG evidence of acute ischemia
• Psychiatric illness/social situations that would limit compliance with study requirements
• No uncontrolled hypertension requiring active manipulation of antihypertensive medications
• No known or active HIV infection
• No history of hypersensitivity to bortezomib, boron, or mannitol
• No peripheral neuropathy > grade 2
• No other malignancy within the past 5 years except curatively treated non life-threatening malignancies, such as cutaneous basal cell or squamous cell carcinoma or carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• Recovered from prior therapy
• Prior stem cell transplantation allowed
• Preparative cytoreductive and high-dose therapies considered 1 prior therapy
• At least 4 weeks since prior cytotoxic chemotherapy (6 weeks since prior nitrosoureas or mitomycin C)
• At least 12 weeks since prior radioimmunotherapy
• One prior course comprising tositumomab or ibritumomab tiuxetan allowed
• At least 1 week since prior palliative steroids for NHL
• No therapeutic monoclonal antibodies (e.g., rituximab, tositumomab, ibritumomab, alemtuzumab, etc.) within 3 months of study entry
• Patients treated with monoclonal antibodies within 3 months allowed provided disease progressed on this therapy AND no treatment received 7 days prior to study entry
• Seven days since prior rituximab (for patients enrolled in phase I portion)
• No major surgery within 4 weeks of study entry
• No other concurrent investigational agents
• No other concurrent anticancer therapy